Treatment of invasive aspergillosis in cancer patients

被引：0
作者：
Auberger J. [1 ]
Russ G. [1 ]
Greil R. [1 ]
Egle A. [1 ]
机构：
[1] IIIrd Med. Dept. with Hematol., Med. Oncology, Hemostaseology, Rheumatology and Infectious Diseases, Salzburg Private Medical University Hospital, 5020 Salzburg
来源：
memo - Magazine of European Medical Oncology | 2011年 / 4卷 / 4期
关键词：
Antifungal treatment; Aspergillus; Cancer; Fungal infections; Immunocompromised; Recommendations;
D O I：
10.1007/s12254-011-0304-1
中图分类号：
学科分类号：
摘要：
Invasive fungal infections (IFI) remain a leading cause of morbidity and mortality in immunocompromised patients. Despite major improvements, it often remains difficult to obtain accurate diagnosis in neutropenic patients. Timely initiation of antifungal treatment in this high-risk population is mandatory to improve survival. Today, clinicians have a choice among a growing armamentarium of novel antifungal agents. Agents such as "veteran" amphotericin B deoxycholate (d-AMB) have been replaced with lipid formulations, and new generation triazoles as well as novel class echinocandins finally offer opportunities to improve prognosis with less systemic toxicity. Clinical decision-making depends on several guidelines, published studies and not least on economic considerations. The current review summarises up-to-date treatment recommendations of the DGHO/AGIHO, and ECIL-3, as well as the recently published 2010 Clinical Practice Guidelines of the IDSA. © Springer-Verlag 2011.
引用
收藏
页码：266 / 272
页数：6
相关论文
共 75 条
  • [11] Pagano L., Akova M., Dimopoulos G., Et al., Risk assessment and prognostic factors for mould-related diseases in immunocompromised patients, J Antimicrob Chemother, 66, SUPPL.. 1, pp. 5-14, (2011)
  • [12] Marr K.A., Carter R.A., Crippa F., Wald A., Corey L., Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients, Clin Infect Dis, 34, pp. 909-917, (2002)
  • [13] Freifeld A.G., Bow E.J., Sepkowitz K.A., Et al., Clinical Practice Guidelines for the Use of Antimicrobial Agents in Neutropenic patients with Cancer: 2010 Update by the Infectious Disease Society of America, Clin Infect Dis, 52, 4, (2011)
  • [14] Morgan J., Wannemuehler K.A., Marr K.A., Et al., Incidence of invasive aspergillosis following hematopoietic stem cell transplantation or solid organ transplantation: Interim results of a prospective multicenter surveillance program, Med Mycol, 43, SUPPL.. 1, (2005)
  • [15] Caillot D., Casasnovas O., Bernard A., Et al., Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery, J Clin Oncol, 15, pp. 139-147, (1997)
  • [16] Maertens J., Theunissen K., Verhoef G., Et al., Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: A prospective feasibility study, Clin Infect Dis, 41, pp. 1242-1250, (2005)
  • [17] Hebart H., Klingspor L., Klingebiel T., Et al., A prospective randomized controlled trial comparing PCR-based and empirical treatment with liposomal amphotericin B in patients after allo-SCT, Bone Marrow Transplant, 43, pp. 553-561, (2009)
  • [18] Segal B.H., Almyroudis N.G., Battiwalla M., Et al., Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts, Clin Infect Dis, 44, 3, pp. 402-409, (2007)
  • [19] Karthaus M., Hentrich M., Wait and see or rush and switch? New questions for the management of patients with febrile neutropenia receiving antifungal prophylaxis, Mycoses, 54, SUPPL.. 1, pp. 1-6, (2011)
  • [20] Wheat L.J., Hackett E., Durkin M., Et al., Histoplasmosis-associated cross-reactivity in the BioRad Platelia Aspergillus enzyme immunoassay, Clin Vaccine Immunol, 14, pp. 638-640, (2007)
12345678